Fenwick & West represented BioAge Labs, Inc. in the offering, and Cooley represented the underwriters. BioAge Labs, Inc. (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic...
You must be a Standard 1 Year member to access this content.
Haynes and Boone is advising BiomX Inc. on the transaction, Cooley is advising Adaptive Phage Therapeutics and Wilmer Cutler Pickering Hale and Dorr is advising the...
You must be a Standard 1 Year member to access this content.
Sullivan & Cromwell represented DraftKings, while Cooley represented Jackpocket in the transaction. DraftKings, a digital sports entertainment and gaming company, has reached an agreement to acquire...
You must be a Standard 1 Year member to access this content.
Leerink Partners is serving as exclusive financial advisor to Tectonic and Cooley LLP is serving as legal counsel to Tectonic. Leerink Partners and TD Cowen are...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advised Neumora, and Cooley advised the underwriters. Neumora Therapeutics, Inc. announced the pricing of its initial public offering of 14,710,000 shares of its common...
You must be a Standard 1 Year member to access this content.
Cooley advised Definitive Healthcare on the deal. Definitive Healthcare (Nasdaq: DH) announced its acquisition of Populi for $52 million in an all-cash transaction. This acquisition furthers Definitive...
You must be a Standard 1 Year member to access this content.
Ropes & Gray acted as legal advisor to TransMedics, and Cooley acted as legal advisor to Bridge to Life. TransMedics Group, Inc. (Nasdaq: TMDX) announced that is...
You must be a Standard 1 Year member to access this content.
Cooley represented Turnstone, and Latham & Watkins represented the underwriters in the IPO. Turnstone Biologics Corp. (Nasdaq: TSBX) announced the pricing of its upsized initial public...
You must be a Standard 1 Year member to access this content.
Goodwin and Freshfields advised argenx, while Cooley advised the representatives of the several underwriters on the offering. argenx SE closed its $1.27 billion follow-on offering. On July 19,...
You must be a Standard 1 Year member to access this content.
Cooley advised ACELYRIN, and Davis Polk advised the joint book-running managers. ACELYRIN, INC. announced its upsized initial public offering of 34,500,000 shares of common stock at...
You must be a Standard 1 Year member to access this content.
Cooley advised SCYNEXIS on the deal. SCYNEXIS announced its exclusive license agreement with GSK for Brexafemme. The exclusive license agreement gives GSK rights to commercialize SCYNEXIS’ ibrexafungerp...
You must be a Standard 1 Year member to access this content.
Cooley LLP represented Structure Therapeutics, while Latham & Watkins LLP represented the underwriters in the offering. Structure Therapeutics, a clinical-stage global biopharmaceutical company, announced its $185.3 million...
You must be a Standard 1 Year member to access this content.
